2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 368

Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Abstract Number: 136

Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis
Abstract Number: 1860

Serum Calprotectin and Disease Relapse in ANCA-Associated Vasculitis
Abstract Number: 988

Serum CXCL13 As a Biomarker of Disease Activity and Severity in Rheumatoid Arthritis: Comparison with Acute Phase Reactants and the Autoantibody Profile
Abstract Number: 523

Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
Abstract Number: 1653

Serum Cystatin C As a Biomarker for Clinical Practice in Patients with Lupus Nephritis
Abstract Number: 807

Serum Cytokine Profiles in Takayasu’s Arteritis: A Search for a Biomarker
Abstract Number: 1598

Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis
Abstract Number: 736

Serum Galectin-3 Levels in Early Diffuse Systemic Sclerosis and the Relationship to Skin Score and Skin Score Change
Abstract Number: 2928

Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Abstract Number: 2582

Serum Levels of Bone Morphogenetic Protein-7 and Sclerostin Are Elevated in Ankylosing Spondylitis, but Not Linked with Structural Damage
Abstract Number: 1715

Serum Levels of CD163/Tweak Predict Risk of Digital Ulcers in Patients with Systemic Sclerosis
Abstract Number: 2925

Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy
Abstract Number: 2661

Serum Neuronal Biomarkers and Brain Atrophy in Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2515

Serum Survivin in Early Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].